M3Cs version 2.0 is an upgrade of M3Cs. M3Cs Version 2.0 is the first specialized microRNA platform in childhood cancer that introduced 'clinical validity' for all microRNAs included in M3Cs 'Clinical Domain' using 'Consensus of M3Cs Standardized Clinical Validity Framework 2024 Version 1.0' which was developed by a panel of experts in the field. M3Cs Version 2.0 utilized digital innovation, as a primer for the introduction of translational bioinformatics approaches and data-driven decision-making, to deliver a unique value microRNA platform. Digital innovation fosters an agile and adaptive organizational strategy with the help of data-driven insights that were needed by M3Cs for evidence synthesis and implementation to move forward from translational bioinformatics to clinical validity toward clinical utility/application in childhood cancer. It encourages journal editors, reviewers, as well as researchers to standardize miRNA clinical publications according to the United Nations SDGs ensuring healthy lives and promoting well-being at all ages are essential to sustainable development. M3Cs Version 2.0 seeks to contribute to the achievement of SDG3 (Good Health and Well-Being) , SDG9 (Innovation and Infrastructure) , and SDG17 (Partnerships) by providing high-quality specialized microRNA platform in translational bioinformatics, evidence synthesis, and clinical validity for childhood cancer diseases. M3Cs Version 2.0 is a standard model that can be applied in other microRNA platforms of various diseases to promote their clinical utility.